HUP0101960A2 - Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them - Google Patents
Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing themInfo
- Publication number
- HUP0101960A2 HUP0101960A2 HU0101960A HUP0101960A HUP0101960A2 HU P0101960 A2 HUP0101960 A2 HU P0101960A2 HU 0101960 A HU0101960 A HU 0101960A HU P0101960 A HUP0101960 A HU P0101960A HU P0101960 A2 HUP0101960 A2 HU P0101960A2
- Authority
- HU
- Hungary
- Prior art keywords
- etm
- compound
- metabolites
- formula
- ecteinascidin
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title abstract 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical class C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 abstract 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 abstract 1
- 102000018832 Cytochromes Human genes 0.000 abstract 1
- 108010052832 Cytochromes Proteins 0.000 abstract 1
- 241000798369 Ecteinascidia turbinata Species 0.000 abstract 1
- 241000289419 Metatheria Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/10—Quaternary compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
A találmány az Ecteinascidia turbinata tengeri zsákállatokból izoláltrákellenes hatású Et 743 humán citokróm CYP3A4 által végzettmetabolizmus termékeire vonatkozik. Ezeket a metabolitokat ETMrövidítéssel illetik, melyet egy, a közelítő molekulatömeget jelentőszám követ. Három vegyület került azonosításra, nevezetesen az ETM 305(II képletű vegyület), az ETM 204 (IV képletű vegyület) és az ETM 775(III képletű vegyület). Szintén a találmány körébe tartozik az ETM 305és az ETM 775 alkalmazása gyógyászati készítmények előállítására,valamint az ilyen vegyületeket tartalmazó gyógyászati készítmények is,amelyek leukémia és különféle daganatos megbetegedések kezelésérealkalmazhatók. ÓThe invention relates to the metabolism products of human cytochrome Et 743 isolated from marine marsupials Ecteinascidia turbinata with anticancer activity by CYP3A4. These metabolites are abbreviated ETM, followed by a significant number that approximates the molecular weight. Three compounds were identified, namely ETM 305 (compound of formula II), ETM 204 (compound of formula IV) and ETM 775 (compound of formula III). Also within the scope of the invention is the use of ETM 305 and ETM 775 for the production of medicinal preparations, as well as medicinal preparations containing such compounds, which can be used to treat leukemia and various cancer diseases. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8502498P | 1998-05-11 | 1998-05-11 | |
| PCT/US1999/010233 WO1999058125A1 (en) | 1998-05-11 | 1999-05-11 | Metabolites of ecteinascidin 743 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101960A2 true HUP0101960A2 (en) | 2001-11-28 |
| HUP0101960A3 HUP0101960A3 (en) | 2003-03-28 |
Family
ID=22188976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101960A HUP0101960A3 (en) | 1998-05-11 | 1999-05-11 | Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US6316214B1 (en) |
| EP (1) | EP1077698B1 (en) |
| JP (2) | JP4583598B2 (en) |
| KR (1) | KR100643092B1 (en) |
| CN (3) | CN100548988C (en) |
| AT (1) | ATE289810T1 (en) |
| AU (1) | AU759281B2 (en) |
| BG (1) | BG65235B1 (en) |
| BR (1) | BR9910419A (en) |
| CA (1) | CA2331593C (en) |
| CZ (1) | CZ302168B6 (en) |
| DE (1) | DE69923965T2 (en) |
| ES (1) | ES2239442T3 (en) |
| HU (1) | HUP0101960A3 (en) |
| IL (2) | IL139607A0 (en) |
| NO (1) | NO318081B1 (en) |
| NZ (1) | NZ508585A (en) |
| PL (1) | PL192409B1 (en) |
| RU (1) | RU2225864C2 (en) |
| SK (1) | SK285069B6 (en) |
| TR (1) | TR200003470T2 (en) |
| WO (1) | WO1999058125A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE289810T1 (en) * | 1998-05-11 | 2005-03-15 | Pharma Mar Sa | ECTEINASCIDINE DERIVATIVES |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| AR035842A1 (en) | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | METHOD OF HEMISINTESIS FOR THE FORMATION OF INTERMEDIARY AND DERIVATIVE COMPOUNDS AND OF STRUCTURES RELATED TO ECTEINASCIDINE AND TETRAHYDROISOCHINOLINPHENOLS AND INTERMEDIARY APPLICATION COMPOUNDS IN SUCH METHOD |
| US7919493B2 (en) | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
| EP1280809B1 (en) | 2000-04-12 | 2005-07-06 | Pharma Mar, S.A. | Antitumoral ecteinascidin derivatives |
| US7420051B2 (en) | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
| MXPA02011319A (en) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Antitumoral analogs of et 743. |
| WO2002040477A2 (en) | 2000-11-03 | 2002-05-23 | President And Fellows Of Harvard College | Saframycins, analogues and uses thereof |
| WO2002036135A2 (en) * | 2000-11-06 | 2002-05-10 | Pharma Mar, S.A. | Compositions for antitumour treatment containing ecteinascidin 743 |
| GB0117402D0 (en) | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| GB0202544D0 (en) * | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| US7407327B2 (en) * | 2003-03-21 | 2008-08-05 | Seagate Technology Llc | Method and system for withstanding shock in a spindle motor bearing |
| PT1689404E (en) | 2003-11-13 | 2008-12-15 | Pharma Mar Sau | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer |
| PT1658848E (en) | 2004-10-29 | 2007-11-05 | Pharma Mar Sa | Formulations comprising ecteinascidin and a disaccharide |
| US20090325971A1 (en) * | 2005-03-02 | 2009-12-31 | The Trustees Of Columbia University In The City Of New York | Pentacyclic Alkaloid Compounds and Methods of Use Thereof |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US20090012157A1 (en) * | 2006-02-06 | 2009-01-08 | Sears Barry D | Sesamol Derivatives as Novel Inhibitors of Arachidonic Acid Formation |
| RU2605335C2 (en) | 2010-11-12 | 2016-12-20 | Фарма Мар, С.А. | Combination therapy with an antitumor alkaloid |
| JOP20190254A1 (en) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | Antitumoral compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4273773A (en) | 1979-09-24 | 1981-06-16 | American Home Products Corporation | Antihypertensive tricyclic isoindole derivatives |
| JPS59225189A (en) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | Quinonamin derivative and its preparation |
| JPS6084288A (en) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | Cyanoquinonamine acetate and its production |
| US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| JP2562162B2 (en) * | 1986-06-09 | 1996-12-11 | ユニバーシティ・オブ・イリノイ | Ectane Acidin 729, 743, 745, 759A, 759B and 770 |
| DK0574857T3 (en) | 1992-06-19 | 1998-05-04 | Hoechst Ag | Polycyclic 31668P and 31668U Compounds, Methods for their Preparation and their Use as Antibiotic or Antitumoral Drugs |
| US5426108A (en) | 1993-11-10 | 1995-06-20 | American Cyanamid Company | Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2 |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5809563A (en) * | 1996-11-12 | 1998-09-15 | Institute For The Development Of Emerging Architectures, Llc | Method and apparatus utilizing a region based page table walk bit |
| US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| HUP0104273A3 (en) * | 1998-04-06 | 2003-12-29 | Univ Illinois | Semi-synthetic ecteinascidins and pharmaceutical compositions containing them |
| ATE289810T1 (en) * | 1998-05-11 | 2005-03-15 | Pharma Mar Sa | ECTEINASCIDINE DERIVATIVES |
| US6124292A (en) | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| AR035842A1 (en) | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | METHOD OF HEMISINTESIS FOR THE FORMATION OF INTERMEDIARY AND DERIVATIVE COMPOUNDS AND OF STRUCTURES RELATED TO ECTEINASCIDINE AND TETRAHYDROISOCHINOLINPHENOLS AND INTERMEDIARY APPLICATION COMPOUNDS IN SUCH METHOD |
| JP2003520801A (en) | 2000-01-19 | 2003-07-08 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Saframycin-ectineacidin family of compounds, their use and synthesis |
| EP1280809B1 (en) | 2000-04-12 | 2005-07-06 | Pharma Mar, S.A. | Antitumoral ecteinascidin derivatives |
| MXPA02011319A (en) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Antitumoral analogs of et 743. |
-
1999
- 1999-05-11 AT AT99924169T patent/ATE289810T1/en not_active IP Right Cessation
- 1999-05-11 HU HU0101960A patent/HUP0101960A3/en unknown
- 1999-05-11 NZ NZ508585A patent/NZ508585A/en unknown
- 1999-05-11 WO PCT/US1999/010233 patent/WO1999058125A1/en active IP Right Grant
- 1999-05-11 BR BR9910419-9A patent/BR9910419A/en not_active IP Right Cessation
- 1999-05-11 TR TR2000/03470T patent/TR200003470T2/en unknown
- 1999-05-11 ES ES99924169T patent/ES2239442T3/en not_active Expired - Lifetime
- 1999-05-11 US US09/309,947 patent/US6316214B1/en not_active Expired - Fee Related
- 1999-05-11 CZ CZ20004183A patent/CZ302168B6/en not_active IP Right Cessation
- 1999-05-11 CN CNB2006100944780A patent/CN100548988C/en not_active Expired - Fee Related
- 1999-05-11 KR KR1020007012616A patent/KR100643092B1/en not_active IP Right Cessation
- 1999-05-11 AU AU40737/99A patent/AU759281B2/en not_active Ceased
- 1999-05-11 CN CNB2005100544181A patent/CN100339375C/en not_active Expired - Fee Related
- 1999-05-11 JP JP2000547976A patent/JP4583598B2/en not_active Expired - Fee Related
- 1999-05-11 SK SK1715-2000A patent/SK285069B6/en not_active IP Right Cessation
- 1999-05-11 CN CNB998085200A patent/CN1195514C/en not_active Expired - Fee Related
- 1999-05-11 CA CA002331593A patent/CA2331593C/en not_active Expired - Fee Related
- 1999-05-11 EP EP99924169A patent/EP1077698B1/en not_active Expired - Lifetime
- 1999-05-11 DE DE69923965T patent/DE69923965T2/en not_active Expired - Lifetime
- 1999-05-11 IL IL13960799A patent/IL139607A0/en active IP Right Grant
- 1999-05-11 RU RU2000131178/04A patent/RU2225864C2/en not_active IP Right Cessation
- 1999-05-11 PL PL344183A patent/PL192409B1/en not_active IP Right Cessation
-
2000
- 2000-11-10 NO NO20005671A patent/NO318081B1/en not_active IP Right Cessation
- 2000-11-10 IL IL139607A patent/IL139607A/en not_active IP Right Cessation
- 2000-12-05 BG BG105023A patent/BG65235B1/en unknown
-
2001
- 2001-10-03 US US09/971,852 patent/US6867334B2/en not_active Expired - Fee Related
-
2004
- 2004-12-10 US US11/009,237 patent/US7115743B2/en not_active Expired - Fee Related
-
2010
- 2010-06-09 JP JP2010131960A patent/JP2010215656A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101960A2 (en) | Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them | |
| HUP0003309A2 (en) | Imidazolyl-cyclic acetals, process for producing them and pharmaceutical compositions containing the same | |
| HUP0100949A2 (en) | Aryl fused azapolycyclic compounds and pharmaceutical compositions containing the same | |
| RU94044677A (en) | Trisubstituted phenyl-derivatives, method of synthesis, pharmaceutical composition | |
| ATE243688T1 (en) | TAXOL DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| HUP0303756A2 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them | |
| HUP0401982A2 (en) | Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds | |
| HUP0100348A2 (en) | Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates | |
| HUP0303016A2 (en) | Xanthine phosphodiesterase v inhibitors, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0104273A2 (en) | Semi-synthetic ecteinascidins and pharmaceutical compositions containing them | |
| HUP0300080A2 (en) | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them | |
| FI946073A0 (en) | Vitamin D series, 20-modified derivatives, process for the preparation of such derivatives, intermediates used in the process, pharmaceutical preparations containing said derivatives and the use of derivatives for the preparation of medicaments | |
| BG104899A (en) | Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis | |
| HUP0500017A2 (en) | Alkyl ether derivatives or salts thereof and pharmaceutical compositions containing them | |
| HUP0102068A2 (en) | A method for chemoprevention of prostate cancer | |
| ATE45153T1 (en) | BENZISOSELENAZOLTHIONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS. | |
| HUP0001385A2 (en) | Pro-drugs and derivatives of camptothecin, process for their preparation, use thereof and pharmaceutical compositions containing them | |
| HUP0204347A2 (en) | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them and their use | |
| JPS5665869A (en) | Novel 22hydroxyalkyll3*4*55trihydroxyypiperidine compound* its manufacture and drug | |
| AP9300561A0 (en) | Antibiotic compounds. | |
| UA27022C2 (en) | Carbasolon derivatives as intermediates for ondansetron synthesis | |
| FI883250A0 (en) | 3-DESMETYL-4 -FLUORMEVALONSYRADERIVAT, FOERFARANDE FOER FRAMSTAELLNING AV DEM, PAO DESSA FOERENINGAR BASERADE PHARMACEUTISKA PREPARAT, ANVAENDNING AV DEM OCH MELLANPRODUKTER. | |
| HUP0101482A2 (en) | Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same | |
| CA2214322A1 (en) | Novel taxoids, preparation thereof, and pharmaceutical compositions containing same | |
| HUP9904638A2 (en) | Use of benzopyrane derivatives for production of pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |